Om Horizon 2020 Sundhed
Med støtte fra Horizon 2020 kan du gennemføre internationale forskningsprojekter, der understøtter EU’s politikker på sundhedsområdet. Virksomheder kan ved succesfuld anvendelse af programmet få:
- € 1-5 mio. til teknologi- og produktudvikling
- IPR – Patentrettigheder
- Netværk til udviklingspartnere
- Adgang til nye markeder
- Teknologi- og videnstilførsel
Formålet med Horizon 2020 Sundhed er at øge den europæiske konkurrenceevne i forhold til resten af verden og skabe nye arbejdspladser.
Muligheder ved Horizon 2020 Sundhed
Mulighederne er til stede for såvel små som store virksomheder uanset branche og teknologiniveau. Det er således også interessant for virksomheder med traditionel produktion og ikke kun for højteknologiske virksomheder. Det afgørende er, at virksomheden enten står over for en teknologisk udfordring, eller har en projektide til at løse en teknologisk/samfundsmæssig problemstilling. Gennem Horizon 2020 Sundhed kan virksomhederne få medfinansiering fra EU til projektets forskning og udvikling.
Opslag under Horizon 2020 Sundhed, vil der blive udbudt til projekter inden for følgende kategorier (se nederst på siden for aktuelle opslag):
- Personalised medicine
- Innovativ sundheds- og plejeindustri
- Infektionssygdomme og fremme af global sundhed
- Innovative sundheds- og plejesystemer - Integration af pleje
- Afkodning af miljøets rolle, herunder klimaændringer, for sundhed og velvære
- Digital transformation i sundhed og pleje
- Digitale løsninger og cybersikkerhed inden for sundhed og pleje
Krav til Horizon 2020 Sundhed
Der er 3 overordnede krav til et projekt for at kunne ansøge om støtte fra Horizon 2020 Sundhed:
- Innovationshøjde - produktet/teknologien skal være ny(t) og løse en Europæisk problemstilling på sundhedsområdet.
- Stort markedspotentiale eller stor samfundsøkonomisk impact – min. €100mio over 5 år.
- Projektet kræver 3 partnere fra 3 forskellige EU-lande.
Nedenfor er vist de kommende ansøgningsfrister under Horizon 2020 Sundhed. Er der tid nok til at nå næste ansøgningsfrist? Vi anbefaler at beregne 1-2 måneder til udarbejdelse af ansøgningen.
Health technology assessment (HTA) is gaining increasing importance across Europe and the world as a tool to support evidence-based decision-making in healthcare. HTA aims to assess the added clinical/therapeutic value of a new health technology compared to the existing standard of care, under the usual circumstances of healthcare practice (relative effectiveness assessment).
Proposals should develop new or improved methodological approaches and frameworks, and foster methodological consensus-building.
SC1-BHC-23-2018: Novel patient-centred approaches for survivorship, palliation and/or end-of-life care
Health conditions linked to end-of-life issues, life-threatening non-communicable diseases, late or long term side effects and consequences of diseases and their treatments impact quality of life and pose an immense societal and economic burden.
Proposals should demonstrate, based on preliminary results, the effectiveness and cost-effectiveness of new, improved or specifically adapted pharmacological and/or non-pharmacological interventions.
SC1-BHC-21-2018: Research on HIV, tuberculosis (TB) and/or hepatitis C (HCV) in patients with mono-, co-infections and/or comorbidities in the context of fostering collaboration with the Russian Federation
ECDC (European Centre for Disease Control) and WHO-Europe (World Health Organisation) report high number of cases for HIV and TB infections (both in incidence and prevalence) in the European regions and in recent years the epidemic situation has deteriorated in Eastern Europe.
Proposals should address one of more of three different subtopics. In performing the research agenda to address one (or more) of the subtopics, the applicants might make use of already established European cohort networks or establish new collaborations thus widening their geographical scope and include HIV, HCV and/or TB mono or co-infected individuals and perform retrospective or prospective studies.
The prevalence and incidence of non-communicable chronic diseases (NCD) has raised sharply in both EU and LAC countries during the last decades and they are by far the leading cause of mortality representing 60% of all deaths worldwide. Furthermore, 70% to 80% of healthcare costs are spent on chronic diseases. With the creation of the Common Research Area, cooperation with CELAC countries is currently intensifying.
SC1-BHC-16-2018: Global Alliance for Chronic Diseases (GACD) - Scaling-up of evidence-based health interventions at population level for the prevention and management of hypertension and/or diabetes
The Global Alliance for Chronic Diseases (GACD) aims to coordinate research on chronic diseases at a global level in order to enhance knowledge exchange across individual projects, and to better understand the impact of socio-economic, cultural, geopolitical and policy on research findings.
Proposals must focus on the scale-up of interventions at population level for hypertension and/or diabetes prevention and/or management in LMIC, and/or in vulnerable populations in HIC.
SC1-BHC-05-2018: International flagship collaboration with Canada for human data storage, integration and sharing to enable personalised medicine approaches
The EU has ample experience in building and running data repositories to support biomedical research. There is a recognised need for tools that allow researchers to manage, exchange and preserve their data efficiently.
Scope: To build a collaboration of stakeholders in Europe and Canada in the domain of repositories storing and sharing human –omics data that will create a framework for long-term cooperation.
SC1-BHC-03-2018: Exploiting research outcomes and application potential of the human microbiome for personalised prediction, prevention and treatment of disease
The human microbiome plays an important role for health. Many different projects in 'metagenomics' and epidemiological research in recent years have delivered new knowledge on associations between the microbiome and a wide range of diseases. Now the challenge is to accelerate the translation of data and knowledge to define balanced healthy conditions and to predict and prevent diseases through the development of personalised approaches and clinical tools.
Proposals should integrate and use high quality microbiome and other -omics data produced by large scale international initiatives.
Advanced therapies are based on gene, cell or tissue-engineered products which are defined and placed on the market according to the terms of Regulation 1394/2007. So far, only a small number of these products have been placed on the market, and of these, most are for rare diseases. However, in recent years, important discoveries and developments, some unprecedented, have been made in molecular and cell biology and in cell technology, which offer improved opportunities for advanced therapies development.
Building on European strengths and using the definition set out in Regulation (EC) 1394/2007, projects should create knowledge and exploitation platforms around innovative concepts for advanced therapy development.
There are a variety of natural and anthropogenic chemicals that can produce adverse effects via a disruption of the body's endocrine (hormone) system, referred to as endocrine disruptors (EDs). EDs are of increasing importance in chemical regulations in the European Union, and draft criteria to identify EDs have recently been presented for two pieces of EU legislation.
New and improved approaches are needed to increase the quality and efficiency of existing methods to meet demanding and evolving regulatory requirements worldwide. In consultation with relevant regulatory bodies, research should improve and harmonise screening and testing protocols/strategies and hazard/risk assessments with better and faster tools, methods or models, including high-throughput and in silico methods (e.g. QSAR) combined with research on adverse outcomes pathways.
SC1-DTH-07-2018: Exploiting the full potential of in-silico medicine research for personalised diagnostics and therapies in cloud-based environments
The progress in computer modelling and simulation applied in disease management is a European strength and various Decision Support Systems have been developed for different medical disciplines. While the market is developing today, addressing the need of more precise and personalised diagnostics and treatments, the proposed software tools and platforms often need to further conquer visibility and trust from users and investors to get implemented in the routine clinical practice.
Proposals are expected to develop and validate software tools and devices for diagnostic or treatment based on computational modelling and simulation applied in biology and physiology.
SC1-DTH-03-2018: Adaptive smart working and living environments supporting active and healthy ageing
Demographic change and the ageing of the population create new heterogeneous challenges for age-friendly living and working environments such as a shrinking workforce and increasing numbers of workers with functional impairments, chronic conditions, care duties or re-integration in the labour market.
Proposals should develop and validate digitally enabled adaptive services and solutions leading to smart work environments for older adults, supporting them to remain actively involved in professional life, helping them to sustain and renew their work and personal life related skills and support independent active and healthy lifestyles while taking into account reduced capabilities due to age-related health risks and conditions.
Large amounts of valuable health data are generated and collected during and between citizens' medical examinations across Europe. However, opportunities to reuse these data for research and better healthcare are often missed because health data continue to be confined in data silos, not matching semantic standards, quality needs and safe data exchange techniques.
The focus is on developing and testing an extensible, secure and interoperable platform in compliance with the General Data Protection Regulation and the Network and Information Systems directive. The work should include the development of a European prototype implementation with embedded security and large scale testing and validation in a set of use cases with demonstrated relevance for citizens' health.
SU-TDS-02-2018: Toolkit for assessing and reducing cyber risks in hospitals and care centres to protect privacy/data/infrastructures
Digital technologies such as Big data, Internet of Things, Robotics, Artificial Intelligence, High Performance Computing, Cloud and Cybersecurity offer new opportunities to transform healthcare systems and delivery, Connected medical devices, in particular if linked to Clinical Information Systems, can bring increased patient safety and efficiency into healthcare system(s). However, ICT infrastructures and data have become critical for the functioning of the hospitals and care systems and due to increasing connectivity, the exposure to risks of cyber-crime is constantly increasing.
Scope: Development and implementation of innovative methods, tools, guidelines or best practices addressing the need for cybersecurity in hospitals including remote care and homecare settings e.g. for assessing risks and vulnerabilities of hospitals.
The increasing number of individuals with co-and multimorbidities poses an urgent need to improve management of patients with multiple co-existing diseases. A better understanding of their causative mechanisms is needed to develop early diagnosis, efficient prevention and monitoring, and better treatments adapted to co- and multimorbid patients throughout their life course.
Proposals should identify and validate causative mechanisms (e.g. molecular, genetic, correlative, drug-drug interaction) combining mental and physical disorders through the integration of basic, pre-clinical and/or clinical research. Applicants should prove the relevance of the identified mechanisms for co-morbid development.
Personalised medicine (PM) has the potential to respond to, among others, the increasing burden of co-morbidities and thus enhance the sustainability of health care systems. With the increasing number of scientific approaches available, it is crucial to demonstrate the benefit of large scale employment of personalised medicine to citizens and healthcare systems.
The pilot projects should demonstrate the benefit for individuals as well as the implementability and economic viability of personalised medicine approaches in real life healthcare settings. The pilots should be tailored to the needs of citizens, making use of a wide variety of data and proposing prediction, prevention or treatment solutions, focussing on diseases with high burden to society and including multi-morbidity conditions if relevant.
In most European countries, absences from work and early retirement due to mental illness have increased in recent years. Mental health conditions such as depression, anxiety and stress represent substantial financial costs for employers and employees, as well as a significant loss for society at large.
Proposals should focus on implementation research on important challenges in mental health in the workplace in the EU. Proposals should develop and implement intervention(s) that an employer/organization can take to promote good mental health and prevent mental illness in the workplace.
Each year, an estimated 213 million women become pregnant and 140 million newborn babies are delivered. However, many of the women and infants receive no appropriate care or care that is below evidence-based standards; others suffer from over-medicalisation. Access to quality care, during and after pregnancy, is essential to ensure good maternal health and the favourable early development of the child.
Proposals should focus on implementation research for improving maternal and child health during the first '1000 days' from pregnancy until two years of age.
SC1-BHC-14-2019: Stratified host-directed approaches to improve prevention, treatment and/or cure of infectious diseases
Despite major advances in development of new drugs and vaccines against infectious diseases, many of the therapies and preventive measures do not result in the expected favourable health outcomes for various reasons. The pathogen might be resistant to the treatment, or a required immune response might not be provoked to contain the infection; the used drug might not reach the pathogen, or the pathogen might escape the host defence mechanisms.
Proposals should test emerging concepts in drug and/or vaccine development in order to address the problem of antimicrobial drug resistance and to optimize therapeutic, curative or preventive measures against infectious diseases of major concern for Europe.
SC1-BHC-02-2019: Systems approaches for the discovery of combinatorial therapies for complex disorders
Many complex disorders pose a challenge to identify the most effective therapeutic interventions because current therapies often target specific aspects of a disease, without achieving complete control or the best possible results for patients.
Research should aim to understand at systems level the pathophysiology of a disorder in groups of patients responding well or poorly to particular therapies and further develop combinatorial therapies tailored to the needs of individuals or stratified patient groups.
Citizens in a rapidly ageing European population are at greater risk of cognitive impairment, frailty and multiple chronic health conditions with considerable negative consequences for their independence, quality of life and for the sustainability of health and care systems. The challenge is to foster large-scale deployment of integrated digital solutions which will bring improved quality of life to citizens while demonstrating significant efficiency gains in health and care delivery across Europe.
A mix of advanced ICT ranging from biophotonics to robotics, from artificial intelligence to big data and from IoT to smart wearables can address these challenges. A platform for smart living at home should integrate these technologies in an intelligent manner.
Photonic technologies for health applications is a very promising field, where the EU has produced significant results during the past decades; however, industrialization is still lagging behind. The challenges are to develop methods that provide the clinicians with photonics enabled tools to improve or to assess the successes of therapies.
For Innovation Actions the focus in on the following themes: Photonics devices to support monitoring therapeutic progress; Sensor-Based Optimization of Production Processes.
For Research and Innovation Actions the focus in on the following themes: Photonics System on Chip/ System in Package for optical interconnect applications; And photonics systems for advanced imaging to support diagnostics driven therapy.
Regenerative medicine offers hope for untreatable disease and the ageing population, improved quality of life and reduced medical costs. However, so far, regenerative medicine has not yet proved itself in the clinic beyond rare diseases or conditions of limited public health importance. With recent scientific discoveries opening up new approaches to regenerative medicine, the challenge is to use these to extend the regenerative approach to major diseases and conditions.
Projects should focus on innovative translational research to develop regenerative processes towards the ultimate clinical goal of addressing unmet clinical needs of large patient groups.
SC1-BHC-13-2019: Mining big data for early detection of infectious disease threats driven by climate change and other factors
A range of factors is responsible for the (re-)emergence of infectious disease threats, including antimicrobial resistance, altering the epidemiology and spread of disease in a changing global environment. These include drivers such as climate change and associated environmental impacts, population growth, unplanned urbanisation and high mobility, as well as animal husbandry or intensive farming practices.
It is expected that proposals develop: the technology to allow the pooling, access, analysis and sharing of relevant data, including next generation sequencing; the innovative bio-informatics and modelling methodologies that enable risk modelling and mapping; and the analytical tools for early warning, risk assessment and monitoring of (re-)emerging infectious disease threats.
SC1-BHC-28-2019: The Human Exposome Project: a toolbox for assessing and addressing the impact of environment on health
Despite the general acknowledgement by the scientific community that 'Genetics load the gun but environment pulls the trigger' when it comes to the causation of major non-communicable diseases (NCDs), there is persistent uncertainty as to the global burden of disease attributable to environmental (including life-style and climatic) factors, including healthcare costs and negative economic impact. Deciphering the human exposome is a novel way of addressing the challenge to improve health and reduce the overall burden of disease.
Applicants should take advantage of the last decade's rapid technological advances which have opened up new opportunities to collect, combine and analyse large data sets offering new possibilities to understand the contribution of environmental factors to the global health burden of common chronic diseases.
SC1-DTH-01-2019: Big data and Artificial Intelligence for monitoring health status and quality of life after the cancer treatment
Currently available methods and strategies for diagnosis and treatment of cancer help clinicians continuously improve quality of care and prevent cancer deaths in the population. However, often rather aggressive treatment, psychological stress (anxiety and depression) can cause physical and psychological problems that may cause long-term after-cure consequences such as similar or other types of cancer, other types of (chronic) diseases and affect the quality of life of a patient. Therefore, the importance of addressing and, if possible, preventing long-term effects of cancer treatment is growing.
Proposals should focus and deliver on how to better acquire, manage, share, model, process and exploit big data to effectively monitor health status of individual patients, provide overall actionable insights at the point of care and improve quality of life after the cancer treatment.
Across the European Union, medicinal products display differences in names, variations in strength or their package size. The unavailability of a specific product may also necessitate substitution in many instances, if a patient is to be timely served in a pharmacy.
This innovation action is expected to support two goals: (i) the cross-border mobility of European patients by offering safer eDispensations across borders, (ii) the implementation of the IDMP standards in Member States drug databases (including a possible linkage to the EU SPOR - Substance, Product, Organisation and Referential master data database) allowing the identification of locally available medicinal products which are equivalent to the one identified in a foreign prescription.
Senior people are statistically at greater risk of cognitive impairment, frailty and multiple chronic health conditions with consequences for their independence, their quality of life (and the one of their families) but also for the sustainability of health and social care systems. There is also increasing evidence that interactions with the environment play an important role in the evolution of the patient's health status and condition.
The scope of this topic is to foster the large-scale pilots for deployment of trusted and personalised digital solutions dealing with Integrated Care, with a view to supporting and extending healthy and independent living for older individuals who are facing permanently or temporarily reduced functionality and capabilities.
Hold dig opdateret
Tilmeld dig vores gratis nyhedsservice og få besked, når der bliver offentliggjort nye deadlines eller tilskudsordninger.Tilmeld
Kan jeres projekt få støtte fra Horizon 2020 Sundhed?
Vi kan hjælpe med at vurdere, om I bør overveje en ansøgning til Horizon 2020 Sundhed. Lad os tage en uforpligtende samtale om jeres mulighed for at få støtte.
Lad os vurdere jeres idé
Vi kan hurtigt fortælle, om offentlig støtte er relevant for jeres projekt. Fortæl os lidt om ideen, så giver vi en overordnet vurdering af støttemulighederne.Fortæl os om jeres projekt
eller ring 61 60 75 08
Få hjælp til din ansøgning
Vi hjælper virksomheder med at opnå offentlig støtte. Det gør vi ved at omsætte gode projekter til gennemarbejdede ansøgninger.
Få hjælp til hele ansøgningsprocessen: